Trial Profile
Post Marketing Surveillance of Roflumilast in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca; Takeda
- 21 Jun 2017 Status changed from recruiting to completed.
- 26 Feb 2014 New trial record